Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411318 | 0.84 | MPO (0.55) | SLC6A4HTR2AMPO | |
| SCHEMBL31411381 | 0.80 | HTR2A (0.58) | SLC6A4HTR2AHTR1AMPO | |
| SCHEMBL31411266 | 0.79 | MPO (0.41) | SLC6A4HTR2AMPO | |
| SCHEMBL31411320 | 0.78 | HTR1A (0.44) | SLC6A4HTR1A | |
| SCHEMBL2404376 | 0.75 | MPO (0.71) | SLC6A4HTR2AHTR1ASLC6A2HTR1B | |
| SCHEMBL31411391 | 0.73 | CHIA (0.33) | HTR2A | |
| SCHEMBL27751008 | 0.73 | MPO (0.41) | SLC6A4HTR2AHTR1AMPO | |
| SCHEMBL10271562 | 0.73 | ITK (0.43) | HTR2AMPO | |
| SCHEMBL29206414 | 0.72 | MPO (0.69) | SLC6A4HTR2AHTR1ASLC6A2HTR1B | |
| SCHEMBL30877253 | 0.72 | MPO (0.69) | SLC6A4HTR2AHTR1ASLC6A2HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | SLC6A4 18/4885HTR2A 94/4885HTR1A 185/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | SLC6A4 18/4885HTR2A 94/4885HTR1A 185/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | SLC6A4 18/4885HTR2A 94/4885HTR1A 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.